Melbourne-based privately owned Australian biotechnology Technovalia has partnered with the Vax4COVID Alliance and BioNet-Asia to start phase one trial of COVIGEN COVID-19 gene-based vaccine.
COVIGEN is a needle-free DNA-based vaccine. It will be the fifth DNA vaccine to enter trial globally and the first in Australia.
The trial will include adults and elderly who are at the highest risk for severe COVID-19 disease. This trial will be based in New South Wales, South Australia and Western Australia with recruitment to start in late 2020.
